Here are the S-3 shelf registrations from Intelligent Bio Solutions Inc. (INBS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow INBS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBS filings page.
Intelligent Bio Solutions Inc. (INBS) is registering 6,211,809 shares of common stock on Form S-3 for resale by existing holders, all issuable upon exercise of outstanding warrants from a September 2026 private placement and related placement agent warrants. The company itself is not selling any shares in this offering and will not receive proceeds from resales; cash will go to the selling stockholders. INBS may receive up to approximately $9.82 million only if all registered warrants are exercised for cash, and it plans to use any such funds for working capital and general corporate purposes. As of September 14, 2026, 3,316,803 shares of common stock were outstanding, so the registered resale amount is large relative to the current share count, which the company notes could weigh on the trading price if sold rapidly. The prospectus highlights prior Nasdaq bid-price deficiency resolved via a December 2025 reverse stock split and notes that continued listing still depends on meeting ongoing Nasdaq requirements. The company’s auditor has included a going-concern explanatory paragraph in the latest annual financial statements, and the prospectus emphasizes extensive risk factors and forward‑looking statement cautions for prospective investors.
Intelligent Bio Solutions Inc. has filed a resale registration statement covering 6,896,550 shares of common stock for selling stockholders. These shares stem from a December 31, 2025 private placement of common stock and warrants, including 105,000 already issued shares and shares underlying Series L pre-funded warrants and Series K-1 and K-2 warrants. The company received approximately $10.0 million in gross proceeds from that private placement at a combined purchase price of $4.35 per share (or pre-funded warrant) plus accompanying warrants.
The company will not receive proceeds from the resale of these shares, but could receive up to about $18.87 million if all 6,791,550 underlying warrant shares are exercised for cash at $0.01 for pre-funded warrants and $4.10 for Series K-1 and K-2 warrants. Shares outstanding were 1,216,142 as of January 2, 2026; this is a baseline figure, not the amount being offered. Intelligent Bio Solutions is an emerging growth medical technology company focused on its Intelligent Fingerprinting drug screening system and has postponed further development of its biosensor platform pending resolution of licensing issues.
Recent corporate actions include a 1-for-10 reverse stock split effective December 15, 2025, implemented to regain compliance with Nasdaq’s $1.00 minimum bid price rule, with Nasdaq subsequently confirming compliance on January 7, 2026. The prospectus notes that the large number of shares registered for resale could pressure the stock price if sold quickly and highlights ongoing risks related to maintaining Nasdaq listing standards.